TriSalus Life Sciences, Inc. (TLSI) Key Metrics
TLSI valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $223.5M
- Enterprise value
- $296.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 5.0 10-yr median 12.1
- Price / book
- 47.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.47
TLSI key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTLSI valuation Price multiples at each fiscal year-end price.
Price / sales+29.9%
5.9
2025 · hover or tap a bar for each year
20212025
Free cash flow yield+23.9 pts
−7.2%
2025 · hover or tap a bar for each year
20212025
TLSI returns How much profit the business earns on the capital it uses.
Return on assets+4.6 pts
−132.3%
2025 · hover or tap a bar for each year
20212025
Free cash flow margin+98.0 pts
−41.9%
2025 · hover or tap a bar for each year
20212025
Asset turnover+25.6%
1.52
2025 · hover or tap a bar for each year
20212025
TLSI per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+7.3%
$1.19
2025 · hover or tap a bar for each year
20212025
Earnings per share
−$1.04
2025 · hover or tap a bar for each year
20212025
Free cash flow per share
−$0.50
2025 · hover or tap a bar for each year
20212025
Book value per share
−$0.89
2025 · hover or tap a bar for each year
20212025
Shares outstanding+43.0%
37.9M
2025 · hover or tap a bar for each year
20212025
TLSI financial health Debt, liquidity and how easily interest is covered.
Net debt−$1.1M
$14.0M
2025 · hover or tap a bar for each year
20212025
Current ratio+38.8%
2.80
2025 · hover or tap a bar for each year
20212025
Interest coverage
-4.9
2025 · hover or tap a bar for each year
20212025
Debt / assets−1.1%
0.97
2025 · hover or tap a bar for each year
20212025
TLSI efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−7 days
47 days
2025 · hover or tap a bar for each year
20212025
Days of inventory−107 days
187 days
2025 · hover or tap a bar for each year
20212025
Days payables outstanding−114 days
138 days
2025 · hover or tap a bar for each year
20212025
Cash conversion cycle+1 days
96 days
2025 · hover or tap a bar for each year
20212025
Capex / revenue+0.9 pts
2.0%
2025 · hover or tap a bar for each year
20212025
TLSI valuation history
Fiscal year-endToday5-year median
TLSI returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TLSI debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TLSI cash returned to shareholders
DividendsBuybacksFree cash flow
TLSI price vs earnings per share
Share price at year-endEPS (right axis)
TLSI key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $264.5M | $132.8M | $223.6M | $297.0M | $308.8M |
| Enterprise value | $278.5M | $147.9M | $213.5M | $289.5M | $320.6M |
| Price / sales | 5.9 | 4.5 | 12.1 | 24.0 | 36.8 |
| Price / book | — | — | — | — | 10.0 |
| EV / sales | 6.2 | 5.0 | 11.5 | 23.4 | 38.2 |
| Earnings yield | −14.8% | −25.0% | −26.5% | −15.9% | −9.3% |
| Free cash flow yield | −7.2% | −31.0% | −22.9% | −11.1% | −7.8% |
| Shareholder yield (dividends + buybacks) | 0.0% | — | 0.0% | — | — |
| Share price at fiscal year-end | $6.98 | $5.01 | $8.45 | $10.03 | $9.88 |
| Per share | |||||
| Revenue per share | $1.19 | $1.11 | $0.70 | $0.42 | $0.27 |
| Earnings per share | −$1.04 | −$1.25 | −$2.24 | −$1.59 | −$0.92 |
| Operating cash flow per share | −$0.48 | −$1.54 | −$1.91 | −$1.09 | −$0.73 |
| Free cash flow per share | −$0.50 | −$1.55 | −$1.93 | −$1.12 | −$0.77 |
| Cash per share | $0.54 | $0.32 | $0.44 | $0.32 | $0.97 |
| Book value per share | −$0.89 | −$0.98 | −$1.02 | −$0.42 | $0.99 |
| Tangible book value per share | −$0.89 | −$0.98 | −$1.07 | −$0.44 | $0.96 |
| Capex per share | $0.02 | $0.01 | $0.02 | $0.03 | $0.04 |
| Debt per share | $0.91 | $0.89 | $0.06 | $0.07 | $1.35 |
| Shares outstanding | 37.9M | 26.5M | 26.5M | 29.6M | 31.2M |
| Change in shares outstanding | +43.0% | +0.1% | −10.6% | −5.3% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | — | — | — | — | −93.3% |
| Return on invested capital (ROIC) | — | — | — | — | −44.4% |
| Return on assets (ROA) | −132.3% | −136.8% | −254.8% | −157.7% | −76.2% |
| Return on tangible assets | −111.0% | −138.6% | −252.9% | −222.7% | −77.9% |
| Free cash flow margin | −41.9% | −139.9% | −276.4% | −267.0% | −285.1% |
| Financial health | |||||
| Total debt | $34.4M | $23.6M | $1.6M | $2.0M | $42.2M |
| Cash & short-term investments | $20.4M | $8.5M | $11.8M | $9.4M | $30.3M |
| Net debt | $14.0M | $15.1M | −$10.2M | −$7.5M | $11.9M |
| Debt / equity | — | — | — | — | 1.37 |
| Debt / assets | 0.97 | 0.99 | 0.06 | 0.09 | 1.11 |
| Current ratio | 2.80 | 2.02 | 1.42 | 0.53 | 5.51 |
| Quick ratio | 2.54 | 1.63 | 1.25 | 0.49 | 5.31 |
| Interest coverage | -4.9 | -11.7 | — | — | -13.6 |
| Working capital | $20.7M | $10.4M | $6.2M | −$15.1M | $28.8M |
| Invested capital | −$19.9M | −$10.8M | −$37.2M | −$19.8M | $42.8M |
| Tangible asset value | −$33.9M | −$25.9M | −$28.2M | −$13.1M | $30.1M |
| Net current asset value | −$36.9M | −$29.2M | −$30.8M | −$17.1M | $28.2M |
| Graham net-net per share | −$1.12 | −$1.34 | −$1.36 | −$0.78 | $0.80 |
| Capital allocation | |||||
| Share buybacks (net) | $0 | — | $20,000 | — | — |
| Capex / revenue | 2.0% | 1.2% | 3.2% | 6.3% | 15.0% |
| Capex / depreciation | 1.47 | 0.46 | 0.86 | 1.97 | 2.71 |
| Stock-based compensation / revenue | 20.2% | 18.5% | 7.6% | 3.0% | 1.3% |
| R&D / revenue | 33.1% | 60.1% | 161.2% | 172.3% | 169.3% |
| SG&A / revenue | 111.1% | 148.8% | 219.0% | 203.4% | 202.5% |
| Efficiency | |||||
| Days sales outstanding | 47.1 | 53.6 | 50.4 | 42.9 | 59.0 |
| Days of inventory on hand | 186.7 | 293.3 | 281.4 | 223.3 | 395.3 |
| Days payables outstanding | 138.2 | 252.0 | 584.1 | 504.9 | 397.7 |
| Cash conversion cycle (days) | 95.5 | 94.9 | -252.4 | -238.7 | 56.5 |
| Receivables turnover | 7.75 | 6.81 | 7.24 | 8.51 | 6.19 |
| Payables turnover | 2.64 | 1.45 | 0.62 | 0.72 | 0.92 |
| Inventory turnover | 1.96 | 1.24 | 1.30 | 1.63 | 0.92 |
| Asset turnover | 1.52 | 1.21 | 0.79 | 0.41 | 0.22 |
| Average receivables | $5.8M | $4.3M | $2.6M | $1.5M | $1.4M |
| Average payables | $2.6M | $2.8M | $4.2M | $3.1M | $1.3M |
| Average inventory | $3.6M | $3.3M | $2.0M | $1.4M | $1.3M |
| Intangibles / total assets | 0.0% | 0.0% | 4.6% | 3.6% | 2.1% |
Computed from TLSI's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TLSI valuation and financial ratios
It ended the year with $34.4 million of debt and $20.4 million in cash and short-term investments, net debt of $14.0 million. The share count rose 21.3% from 31.2M to 37.9M over 4 years.
See the TLSI income statement, the TLSI chart for price history, or the TLSI stock overview for the latest quote and news.
TLSI key metrics FAQ
How much debt does TriSalus Life Sciences have?
TriSalus Life Sciences had total debt of $34.4 million at the end of fiscal 2025.
What is TriSalus Life Sciences's free cash flow yield?
TriSalus Life Sciences generated -$18.9 million of free cash flow in fiscal 2025, a free cash flow yield of −7.2% on its market value at year-end ($264.5 million).
What is TriSalus Life Sciences's current ratio?
TriSalus Life Sciences's current ratio was 2.80 at the end of fiscal 2025: current assets were 2.80 times current liabilities.